We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-1.15%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.35B
AUM Growth
-$748M
Cap. Flow
-$582M
Cap. Flow %
-24.75%
Top 10 Hldgs %
32.94%
Holding
108
New
18
Increased
28
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$43.9M
2
CGEM icon
Cullinan Oncology
CGEM
+$33.2M
3
INCY icon
Incyte
INCY
+$30M
4
TMO icon
Thermo Fisher Scientific
TMO
+$24.9M
5
ARGX icon
argenx
ARGX
+$23.2M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$139M
2
ALGN icon
Align Technology
ALGN
+$62M
3
BSX icon
Boston Scientific
BSX
+$57.5M
4
LLY icon
Eli Lilly
LLY
+$54.5M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Technology 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
51
Phathom Pharmaceuticals
PHAT
$849M
$16.7M 0.71%
1,620,000
-115,000
-7% -$1.18M
AZN icon
52
AstraZeneca
AZN
$255B
$16M 0.68%
102,500
+22,500
+28% +$3.39M
KROS icon
53
Keros Therapeutics
KROS
$210M
$15.7M 0.67%
343,200
+133,500
+64% +$7.17M
BHVN icon
54
Biohaven
BHVN
$2.24B
$15.6M 0.66%
450,000
+375,000
+500% +$14.8M
SNY icon
55
Sanofi
SNY
$105B
$15.3M 0.65%
+315,000
New +$15.2M
RGNX icon
56
Regenxbio
RGNX
$557M
$15.2M 0.65%
1,300,064
– –
CNTX icon
57
Context Therapeutics
CNTX
$56.6M
$14.9M 0.63%
+7,419,355
New +$12.8M
EXAS
58
DELISTED
Exact Sciences
EXAS
$14.3M 0.61%
+338,500
New +$18.6M
PRVA icon
59
Privia Health
PRVA
$3.31B
$13.3M 0.56%
764,200
– –
NAMS icon
60
NewAmsterdam Pharma
NAMS
$3.47B
$10.7M 0.46%
559,300
+84,300
+18% +$1.69M
IMNM icon
61
Immunome
IMNM
$2.51B
$10.6M 0.45%
873,891
– –
IMUX icon
62
Immunic
IMUX
$204M
$9.88M 0.42%
890,297
– –
CRBP icon
63
Corbus Pharmaceuticals
CRBP
$165M
$9.76M 0.41%
+215,600
New +$9.07M
HELP
64
Cybin Inc
HELP
$441M
$9.45M 0.4%
918,000
– –
SYRS
65
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.64M 0.37%
1,673,538
– –
COGT icon
66
Cogent Biosciences
COGT
$6.54B
$8.44M 0.36%
1,000,706
+555,000
+125% +$4.21M
IMCR icon
67
Immunocore
IMCR
$1.73B
$6.78M 0.29%
200,000
-86,400
-30% -$4.41M
TYRA icon
68
Tyra Biosciences
TYRA
$1.85B
$5.96M 0.25%
+373,000
New +$6.42M
PATH icon
69
UiPath
PATH
$6.3B
$4.59M 0.2%
+362,000
New +$6.26M
SYRE icon
70
Spyre Therapeutics
SYRE
$8.45B
$4.58M 0.19%
+195,000
New +$6.58M
IMTX icon
71
Immatics
IMTX
$1.26B
$4.57M 0.19%
+393,100
New +$4.43M
IONS icon
72
Ionis Pharmaceuticals
IONS
$8.75B
$4.43M 0.19%
93,000
-37,000
-28% -$1.52M
ORKA
73
Oruka Therapeutics
ORKA
$5.53B
$3.83M 0.16%
+83,333
New +$3.32M
EDIT icon
74
Editas Medicine
EDIT
$442M
$3.81M 0.16%
+816,000
New +$4.6M
NTLA icon
75
Intellia Therapeutics
NTLA
$1.53B
$3.8M 0.16%
+170,000
New +$4.05M
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
CM
Columbus Macro New Castle, Pennsylvania $936M AUM 12.9% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return

Avidity Partners Management's Q2 2024 Portfolio in Review

As of Q2 2024, Avidity Partners Management held 108 positions worth $2.35B, down 24% from $3.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $582M in Q2 2024, closing 23 positions and reducing 25 holdings. Its most notable exit was Fusion Pharmaceuticals Inc. Common Shares, an estimated $139M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in Perspective Therapeutics worth $30.3M.

  • Avidity Partners Management's largest Q2 2024 buy was Perspective Therapeutics: 3,037,668 shares worth $30.3M.
  • Avidity Partners Management added most to Thermo Fisher Scientific in Q2 2024, an estimated $24.9M increase.
  • Avidity Partners Management's biggest Q2 2024 reduction was Boston Scientific, cutting an estimated $57.5M.
  • Avidity Partners Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $139M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.35B portfolio in Q2 2024.
  • Avidity Partners Management opened 18 new positions and closed 23 in Q2 2024.
  • Avidity Partners Management's portfolio value fell 24% quarter-over-quarter to $2.35B.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.